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of management by reducing the number of ischemic com-
plications.
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FRANCE
Annemans L1,2, Moeremans K2, Aliot E3, de Jong P4
1Free University of Brussels, Brussels, Belgium; 2HEDM, 
Mechelen, Belgium; 3Hopital Central, Nancy, France; 4Biosense, 
Waterloo, Belgium
OBJECTIVES: Despite multiple pharmacological treatment
many patients with atrial fibrillation (Afib) are not com-
pletely “arrhythmia-free,” and remain at risk of chronic
complications such as stroke and cardiac morbidity. Cur-
rently, if first line treatment fails, most patients receive sec-
ond line pharmacological treatment. The emergence of new
technologies, aiming at “curing” the arrhythmia, e.g., com-
puter guided ablation techniques, has increased interest in
the economic aspects of current second line pharmacologi-
cal treatment of Afib. Therefore, we analyzed the average 5-
year costs of second-line pharmacological management of
paroxysmal and persistent Afib in France.
METHODS: The two most relevant current treatment
strategies were included: (1) rhythm control, i.e., com-
bined therapy with class Ic and III antiarrhythmics and (2)
rate control, i.e., digoxin therapy together with a beta-
blocker or a calcium antagonist. Both strategies are often
combined with either anticoagulation therapy or aspirin.
The analysis included probabilities of stroke, sudden death
and other cardiac or non-cardiac death, and direct medical
costs of drugs, follow-up and prevention or treatment of
complications from a health care insurance perspective
(discounted at 3% per annum). Clinical data were col-
lected from prospective randomized clinical trials, medical
resource use was obtained from expert opinion (two
round pure Delphi panel) from 10 centers, and unit costs
were obtained from official sources.
RESULTS: The average total 5-year cost of pharmaco-
logical management of Afib was FF108,500 per patient
(SD  66,300; MIN  26,500; MAX  335,000). Fol-
low-up visits and hospitalizations represented the largest
proportion of costs (39%), followed by the cost of treat-
ing congestive heart failure (CHF) (33%). Patients with
prevalent CHF at start cost on average FF149,000. Pa-
tients with persistent Afib cost on average FF40,000
more than patients with paroxysmal Afib.
CONCLUSIONS: Current second line pharmaceutical
management of Afib is expensive and provides opportu-
nities for new surgical or medical interventions.
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Telmisartan (Micardis®) is a new A-II inhibitor licensed
in the UK for the treatment of people with mild to mod-
erate hypertension. Randomised controlled trials (RCTs)
suggest that the clinical outcomes of treatment with telm-
isartan may compare favorably with other products in its
class as well as with products in other classes. Therefore
the purpose of this analysis is to evaluate the extent to
which the clinical benefits are translated into economic
benefits from the perspective of the UK NHS.
Data pertaining to key clinical outcomes (efficacy and ad-
verse events) are derived from RCTs comparing telmisar-
tan with several alternative medications. The ranges are
validated by a review of the clinical literature. The costs
of hypertension treatment and the management of ad-
verse events are derived from treatment algorithms and
published sources. The clinical and cost data are com-
bined in a decision-analytic model to perform four sets of
analyses:
1. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and outcomes
2. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and outcomes
3. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
4. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
The results are reported in both cost-effectiveness and
cost-consequences format and are evaluated for their sen-
sitivity to changes in key parameter values. The policy
implications and directions for future research are dis-
cussed.
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OBJECTIVES: To evaluate hospital utilization in patients
with atrial fibrillation or flutter (AF/F) using a managed
care claims database.
METHODS: A longitudinal integrated medical and phar-
macy claims database was used to identify patients who
received an AF/F diagnosis in the emergency room and/or
hospital in calendar year 1995. The earliest date for ei-
ther primary or secondary diagnosis of AF/F was desig-
nated as the index date for the purpose of analysis. Hos-
pital utilization both before and after the index date was
obtained for four AF/F patient cohorts: patients with no
history of congestive heart failure (CHF), myocardial inf-
arction (MI) or stroke as recorded within the last 12
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months of the index date including the index date (cohort
Cnn), patients with no CHF but MI or stroke (cohort Cny),
patients with CHF but no MI or stroke (cohort Cyn), and
patients with both CHF and MI or stroke (cohort Cyy).
RESULTS: Number of patients identified for cohorts Cnn,
Cny, Cyn and Cyy were 319, 91, 195 and 59; among them
52%, 41%, 52%, and 47% were female, respectively.
The mean ages of patients in cohorts Cnn, Cny, Cyn and Cyy
were 68.5, 73.5, 75.2, and 76, respectively. The follow-
ing table shows the hospital utilization (percent of AF/F
patients hospitalized for any reason):
CONCLUSIONS: Cost intensive resource utilization, such
as hospitalization, increases up to 139.3% after the diag-
nosis of AF/F as recorded in a managed care claims data-
base. Although patients with concomitant illnesses, such
as CHF, MI, and stroke, have higher hospital utilization
compared to patients without such diseases, AF/F con-
tributes to the highest percentage increase for the healthi-
est patient population.
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BACKGROUND: A disease model was developed to com-
pare clinical and economic outcomes of home monitoring
versus ambulant monitoring in anticoagulation patients
with heart valve implants in two different locations. The
improved outcomes seen with home monitoring result from
tighter control of the anticoagulation (AC) level. Thereby a
higher proportion of patients is kept within the therapeutic
INR target range leading to a decreased incidence of ad-
verse events.
OBJECTIVE: The model compares the event-rates of ma-
jor thromboembolic events (TE), major bleeding (BL) com-
plications and mortality rates in cohorts with mechanical
heart valve replacement requiring oral anticoagulation with
warfarin.
METHODS: The AC monitoring strategies compared
were A) 52 times/year home monitoring of AC with the
CoaguChek home-monitor, and B) monthly monitoring
in an outpatient clinic (with laboratory tested AC levels).
Direct costs of basic treatment, patient education and mon-
itoring, as well as treatment costs of complications were
collected from the Swiss third party payer perspective. Com-
plication rates (TE, BL, mortality) were derived from pub-
lished literature and official agency reports. The health eco-
nomic analysis simulated an observational time of 10 years.
Cost outcomes were discounted at a real annual rate of 5%.
RESULTS: Self-monitoring by patients reduces the total
costs (monitoring and complication related costs) per pa-
tient from Swiss Francs (CHF) 8’988 to CHF 7’532 per pa-
tient over the observation time of 10 years. Sensitivity anal-
ysis were performed and identified the main cost drivers as:
frequency of home monitoring, cost per home monitoring
test, cost and durability of home monitoring device.
CONCLUSION: Demonstrated within the limitations of
the modelling approach, the application of home monitor-
ing in heart valve implant patients is dominant to ambulant
monitoring in outpatient clinics, with increased life quality
and decreased overall costs.
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BACKGROUND: High serum lipid levels are an impor-
tant risk factor for cardiovascular disease such as myocar-
dial infarction and stroke. Recently, an American study
demonstrated that 5 years after beginning treatment, ap-
proximately half of the cohort studied had stopped statin
therapy.1 The aim of our study was to estimate adherence
to statins in Tayside and to determine if co-morbidity, so-
cial deprivation, and co-prescribing were predictors of ad-
herence.
METHODS: Two studies were performed: Study 1, to de-
termine adherence to statins over a 5-year period of follow-
up and predictors of that adherence. Study 2, to find pre-
dictors of compliance with statins in a 13-month follow-up
period after publication of the 4S-study.2 The study popula-
tion consisted of all individuals from the fixed population
base who received more than one prescription for a statin.
For each individual, adherence to therapy was defined as
the days for which statins had been dispensed divided by
the number of days they should have been dispensed. Peo-
ple who had statins dispensed for 85% or more of their
days in the community were classified as adherent. Logistic
regression analyses were performed to determine predictors
of short-term and long-term adherence.
RESULTS: Study 1. After 5 years, 65% of the original co-
hort (n  392) were still collecting prescriptions for statins.
89 (23%) were adherent to statin therapy. Predictors of
adherence were cardiovascular disease (OR: 1.19), female
gender (OR 1.67), and co-prescribing of nitrates (OR
1.62). Study 2. Of the 1548 people who received a statin,
652 (42%) were adherent to therapy. In this study, predic-
tors were age (OR 1.02), use of nitrates (OR 0.76), and di-
abetes (OR 0.65).
Cnn Cny Cyn Cyy Total
Before index date 13.5 35.2 33.9 47.5 25.5
After index date 32.3 42.9 57.4 54.2 43.1
Percent increase 139.3 21.9 69.3 14.1 69.0
